Comparison of obinutuzumab and rituximab for treating primary membranous nephropathy.
Xiaofan HuMuyin ZhangJing XuChenni GaoXialian YuXiao LiHong RenWeiming WangJingyuan XiePublished in: Clinical journal of the American Society of Nephrology : CJASN (2024)
Our study demonstrated that obinutuzumab is associated with higher odds of clinical remission compared to rituximab at 12 months which may be due to higher immunological remission at six months with a similar safety profile in patients with primary membranous nephropathy.